Thursday, October 27, 2016 10:00:08 AM
After reviewing the past few years of revenues, I see that Q3 is historically lower. And I think the UK is getting tired of the ActiPatch.
Long term, I don't think BIEL will EVER sell enough of the ActiPatch to pay off their debt and turn a profit. FDA OTC Clearance will extend the life of this zombie biotech but the USA will just be another place for the ActiPatch to fail.
But short term... $525k revenues in Q3 sounds about right. I'd go even lower, but there's no way of knowing how many Trial Version units they are selling in Australia and New Zealand.
They probably borrowed another $550k and paid another $330k in debt interest and probably lost around $220,000 from Operations. In other words -- business as usual.
I challenge the company to breakout their sales by country so we can see the UK sales but I doubt they will -- they discovered we were looking at that last quarter and stopped disclosing that breakout.
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM